Journal Title
Title of Journal: Curr Urol Rep
|
Abbravation: Current Urology Reports
|
Publisher
Current Science Inc.
|
|
|
|
|
|
Authors: Mohamed Ismail Matthew Ferroni Leonard G Gomella
Publish Date: 2011/03/08
Volume: 12, Issue: 3, Pages: 188-196
Abstract
Androgen suppression therapy AST was first described in 1941 as a treatment of prostate cancer PCa and remains the mainstay of therapy in patients with hormonenaïve metastatic disease It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higherrisk features Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levelsM Ismail none M Ferroni none Dr Leonard Gomella has served as a consultant for Amgen Bayer Centocor Ortho Biotech Inc Watson Pharmaceuticals and GlaxoSmithKline received honoraria from all and has received grants or has grants pending from VIVUS Inc Amgen and Centocor Ortho Biotech Inc
Keywords:
.
|
Other Papers In This Journal:
|